Key PointsPatient Square Capital LP initiated a new position in Nektar Therapeutics, buying 210,000 shares—an estimated $11.96 million trade based on quarterly average pricing
Key PointsPatient Square Capital LP initiated a new position in Nektar Therapeutics, buying 210,000 shares—an estimated $11.96 million trade based on quarterly average pricing
In this article TSLA Follow your favorite stocks CREATE FREE ACCOUNT Tesla raised the prices of its Model Y cars in the United States on Saturday, according to its website. The company increased the price of its Model Y premium all-wheel drive and Model Y premium rear-wheel drive by $1,000 to $49,990 and $45,990 respectively. The company also raised the price of its Model Y Performance all-wh...
In this article TSLA Follow your favorite stocks CREATE FREE ACCOUNT Tesla raised the prices of its Model Y cars in the United States on Saturday, according to its website. The company increased the price of its Model Y premium all-wheel drive and Model Y premium rear-wheel drive by $1,000 to $49,990 and $45,990 respectively. The company also raised the price of its Model Y Performance all-wheel drive to $57,990 in the United States, up $500 from earlier, the website showed. In August last year, the company raised the price of its most-expensive Cybertruck pickup truck model by $15,000 in the United States despite softer-than-expected sales and recalls. Tesla did not provide a reason for the price increase. The last time the company increased the price of Model Y cars was two years ago in 2024 when it raised the prices of all Model Y cars by $1,000. Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Key PointsFor decades, Warren Buffett has said most retail investors are better off owning a long-term portfolio of large-cap stocks instead of stock picking.
Key PointsFor decades, Warren Buffett has said most retail investors are better off owning a long-term portfolio of large-cap stocks instead of stock picking.
Thai authorities say 32 others injured near Makkasan station after freight train strikes bus and fire breaks out At least eight people were killed and 32 others were injured in Thailand after a freight train struck a bus at a rail crossing in Bangkok, rescue officials and a deputy transport minister said. Firefighters and rescue crews were dispatched as flames engulfed the bus and nearby vehicles ...
Thai authorities say 32 others injured near Makkasan station after freight train strikes bus and fire breaks out At least eight people were killed and 32 others were injured in Thailand after a freight train struck a bus at a rail crossing in Bangkok, rescue officials and a deputy transport minister said. Firefighters and rescue crews were dispatched as flames engulfed the bus and nearby vehicles close to the airport rail link’s Makkasan station, officials said, adding that the collision also involved cars and motorcycles. Continue reading...
Jeffrey M. Stibel, Chief Executive Officer of LegalZoom.com (NASDAQ:LZ) , reported an open-market purchase of 125,000 shares, valued at approximately ~$769,000, according to a SEC Form 4 filing dated May 11, 2026. Transaction and post-transaction values based on SEC Form 4 weighted average purchase price ($6.15). * 1-year performance is calculated using May 11, 2026 as the reference date. Continue...
Jeffrey M. Stibel, Chief Executive Officer of LegalZoom.com (NASDAQ:LZ) , reported an open-market purchase of 125,000 shares, valued at approximately ~$769,000, according to a SEC Form 4 filing dated May 11, 2026. Transaction and post-transaction values based on SEC Form 4 weighted average purchase price ($6.15). * 1-year performance is calculated using May 11, 2026 as the reference date. Continue reading
This week, Ray Dalio explains why markets shrug off wars and why this time might be different. And, why are AI executives warning about the dangers of systems they are simultaneously racing to build? Plus, China’s massive investments in energy infrastructure are increasingly shaping the global competition for artificial intelligence leadership and industrial power. Later, can New York remain attra...
This week, Ray Dalio explains why markets shrug off wars and why this time might be different. And, why are AI executives warning about the dangers of systems they are simultaneously racing to build? Plus, China’s massive investments in energy infrastructure are increasingly shaping the global competition for artificial intelligence leadership and industrial power. Later, can New York remain attractive to businesses and young workers while raising taxes to close a growing budget shortfall? (Source: Bloomberg)
Big Tech's embrace of Formula (FWONK) 1 isn't exactly breaking news, as the data heavy sport is a natural partner. But now chipmakers are getting to the game too.
Big Tech's embrace of Formula (FWONK) 1 isn't exactly breaking news, as the data heavy sport is a natural partner. But now chipmakers are getting to the game too.
Apple has agreed to a preliminary $250 million nationwide class action settlement over alleged false advertising of its "Apple Intelligence" features. The proposed deal would compensate U.S. consumers and businesses that bought affected iPhones marketed with the advanced AI capabilities. The settlement is pending court approval and follows claims that the promoted AI features did not match real wo...
Apple has agreed to a preliminary $250 million nationwide class action settlement over alleged false advertising of its "Apple Intelligence" features. The proposed deal would compensate U.S. consumers and businesses that bought affected iPhones marketed with the advanced AI capabilities. The settlement is pending court approval and follows claims that the promoted AI features did not match real world performance. For investors tracking NasdaqGS:AAPL, this potential $250 million payout is...
(RTTNews) - Ipsen SA (IPN.PA, IPSEY) presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen's first-in-class recombinant neuroinhibitor, RNITM.
(RTTNews) - Ipsen SA (IPN.PA, IPSEY) presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen's first-in-class recombinant neuroinhibitor, RNITM.
Luis Alvarez/DigitalVision via Getty Images Thesis STAAR Surgical Company ( STAA ) delivered a pretty strong 1Q26 beat, with the share price also seeing a boost. Non-GAAP EPS managed to hit $0.48, a figure $0.40 above expectations, whilst revenue reached $93.5 million and exceeded estimates by about $14.78 million. So there was a topline surge of about 119% year over year, which I feel we can put ...
Luis Alvarez/DigitalVision via Getty Images Thesis STAAR Surgical Company ( STAA ) delivered a pretty strong 1Q26 beat, with the share price also seeing a boost. Non-GAAP EPS managed to hit $0.48, a figure $0.40 above expectations, whilst revenue reached $93.5 million and exceeded estimates by about $14.78 million. So there was a topline surge of about 119% year over year, which I feel we can put down to a rebound in China, whilst ex-China sales still grew a modest 6%. So that would indicate some underlying stability here. As for profitability, things improved quite significantly, with gross margins hitting 73.6% and the company managing to swing to $5.2 million in net income compared to a hefty loss last year. In an upside scenario here, I see STAAR sustaining high-teens to 20% plus revenue growth. Now, this would be driven by continued China momentum, but also the accelerating adoption of EVO+ ICL, particularly as premium pricing helps with their margins. If we do see operating leverage continue to materialise, with gross margins trending more toward 75% and OpEx discipline staying decent, then the company could scale into double-digit operating margins faster than expected here. This would support a meaningful earnings ramp and also validate the market’s current growth expectations. 1Q26 As you know, STAAR has just released their 1Q26 results , and there’s definitely a pretty clear operational and financial turnaround taking place from the disruption we saw last year. Revenue managed to reach $93.5 million, a figure more than double that of the same time last year. We can mainly put this down to a rebound in China after some inventory normalisation and renewed procedure demand. What’s important here is that this growth was not actually just a rebound effect, but their core business trends also improved. We can see 6% growth excluding China and about double-digit gains in the U.S. Profitability also saw a pretty dramatic inflection, with gross margins expanding to...
Mastercard (NYSE:MA) announced a deal to acquire BVNK, a platform that connects crypto and traditional payments, as part of its global digital payments strategy. The UK Financial Conduct Authority has opened a competition investigation into Mastercard's digital wallet arrangements. Mastercard also launched a new partnership with JD.com to develop AI-powered and agentic commerce solutions that inte...
Mastercard (NYSE:MA) announced a deal to acquire BVNK, a platform that connects crypto and traditional payments, as part of its global digital payments strategy. The UK Financial Conduct Authority has opened a competition investigation into Mastercard's digital wallet arrangements. Mastercard also launched a new partnership with JD.com to develop AI-powered and agentic commerce solutions that integrate its payment infrastructure. For investors watching NYSE:MA, these moves highlight how a...
jetcityimage/iStock Editorial via Getty Images Summary Wyndham Hot els & Resorts stock is up around 7% YTD but I do not expect any sustainable share price increase given management's recent guidance of flattish earnings growth this year in terms of EPS and RevPAR which are both slowing on a yoy basis compared to 2025. While the company has seen good room inventory growth and has a strong room buil...
jetcityimage/iStock Editorial via Getty Images Summary Wyndham Hot els & Resorts stock is up around 7% YTD but I do not expect any sustainable share price increase given management's recent guidance of flattish earnings growth this year in terms of EPS and RevPAR which are both slowing on a yoy basis compared to 2025. While the company has seen good room inventory growth and has a strong room build pipeline, none of that is contributing to strong earnings growth. An uncertain demand environment in the near term may not result in significant pricing upside for hotels. I rate the stock as a HOLD given limited share price catalysts. Company background Wyndham Hotels & Resorts ( WH ) is one of the largest hotel franchisers worldwide. The company does not own any hotels and this asset light model enables revenues to grow quickly through marketing fees, royalties, ancillary revenue and initial start-up fees. WH has a room inventory of 869k across 25 brands and 8,400 hotels . The hotels are spread over 100 countries mainly targeting the leisure travel segment. WH operates hotels across all economic demographic segments including premium (Registry Collection, Dolce), upscale (Wyndham, Vienna House), midscale (La Quinta, Hawthorn Suites) and economy (Days Inn, Super 8, Travelodge), specialized/vacation (Waterwalk, WorldMark). As of 1Q26 , 58% of WH's rooms are located within the United States. WH 10-Q Royalties/franchise fees along with marketing/reservation/loyalty fees make up the majority of revenue. With the exception of franchise fees which are initially paid upon franchise setup, the remaining fees are paid from a percentage of gross revenue from the franchisee ( ~10% of revenue) . 1Q26 review - flat all around 1Q26 results beat analyst estimates for both revenue and EPS. Revenue came in at $327m (+3% yoy, consensus $320m). Headline EPS was $0.96 (+12% yoy, consensus $0.85). However, adjusted EBITDA of $327m was -1% yoy on a comparable basis. Despite the beat, the shar...
Khadija Shaw set the agenda again, scoring her 20th and 21st goals in 22 WSL games in what could be her penultimate game in sky blue as City secured a comfortable win over West Ham before they hoisted the WSL trophy aloft for the first time in 10 years. What will Manchester City look like without the Jamaican forward? City fans will be hoping they don’t have to find out, but with bigger offers in ...
Khadija Shaw set the agenda again, scoring her 20th and 21st goals in 22 WSL games in what could be her penultimate game in sky blue as City secured a comfortable win over West Ham before they hoisted the WSL trophy aloft for the first time in 10 years. What will Manchester City look like without the Jamaican forward? City fans will be hoping they don’t have to find out, but with bigger offers in from other clubs the striker is leaving unless the club do a sharpest and most grovelling of u-turns. Continue reading...
According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Patient Square Capital LP disclosed the purchase of 210,000 shares of Nektar Therapeutics (NASDAQ:NKTR) . The estimated value of the trade was $11.96 million based on the average closing price for the first quarter of 2026. The quarter-end value of this new position stood at $15.11 million, reflecting the valuation ...
According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Patient Square Capital LP disclosed the purchase of 210,000 shares of Nektar Therapeutics (NASDAQ:NKTR) . The estimated value of the trade was $11.96 million based on the average closing price for the first quarter of 2026. The quarter-end value of this new position stood at $15.11 million, reflecting the valuation shift, including price movement. Nektar Therapeutics is a clinical-stage biotechnology company focused on advancing novel immunotherapies for cancer and autoimmune conditions. Leveraging a robust pipeline and strategic collaborations with leading pharmaceutical companies, Nektar aims to address significant gaps in current treatment options. The company's expertise in cytokine engineering and immunomodulation positions it as a key innovator within the biotechnology sector. If Patient Square acquired its new Nektar Therapeutics Position in the first half of the first quarter, it was a very lucrative bet for the firm. Shares of the biopharmaceutical company more than doubled in February after the company reported successful results from the phase 2b Rezolve-AD clinical trial, which treated eczema patients with rezpegaldesleukin. Continue reading